Stay updated with breaking news from Specific Population. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Applying a simple model of clinical and demographic features associated with GBA mutation carrier status could help target genetic testing in patients with Parkinson's disease, suggests a new study.
-- Statistically significant differences demonstrated between DAYBUE™ and placebo on efficacy endpoints relevant to Rett syndrome suggest treatment potentially capable of modifying core... | June 8, 2023
Acadia Pharmaceuticals Inc. today announced that four posters in Rett syndrome will be presented at the upcoming American Academy of Neurology annual meeting, being held April 22 – 27, 2023... | April 20, 2023
-- Commercial launch of DAYBUE offers Rett syndrome community the first and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000 to 9,000 patients in the... | April 17, 2023